NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291

NervGen Pharma Corp. announced a leadership transition with Dr. Adam Rogers appointed as Interim CEO, following the positive topline results from the ...
Home/KnloSights/Clinical Trial Updates/NervGen Announces Leadership Transition and Positive Chronic Spinal Cord Injury Trial Results for NVG-291